Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma

To provide a more precise estimate of long-term survival observed for ipilimumab-treated patients with advanced melanoma, we performed a pooled analysis of overall survival (OS) data from multiple studies. The primary analysis pooled OS data for 1,861 patients from 10 prospective and two retrospecti...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of clinical oncology 2015-06, Vol.33 (17), p.1889-1894
Hauptverfasser:	Schadendorf, Dirk, Hodi, F Stephen, Robert, Caroline, Weber, Jeffrey S, Margolin, Kim, Hamid, Omid, Patt, Debra, Chen, Tai-Tsang, Berman, David M, Wolchok, Jedd D
Format:	Artikel
Sprache:	eng
Schlagworte:	Antibodies, Monoclonal - administration & dosage Antibodies, Monoclonal - adverse effects Antibodies, Monoclonal - therapeutic use Antineoplastic Agents - administration & dosage Antineoplastic Agents - adverse effects Antineoplastic Agents - therapeutic use Clinical Trials, Phase II as Topic Clinical Trials, Phase III as Topic Drug Administration Schedule Follow-Up Studies Humans Ipilimumab Kaplan-Meier Estimate Melanoma - drug therapy Melanoma - secondary Original Reports Prospective Studies Retrospective Studies Skin Neoplasms - drug therapy Skin Neoplasms - pathology Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!